ArticleArchives of medical science : AMS2026
The association of low-density lipoprotein cholesterol with apolipoprotein B ratio and sarcopenia: a cross-sectional study.
Article in Archives of medical science : AMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond traditional lipid markers: low-density lipoprotein cholesterol with apolipoprotein B ratio - a novel biomarker for sarcopenia?Archives of medical science : AMS · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sarcopenia is increasingly linked to metabolic dysregulation, including dyslipidemia. The low-density lipoprotein cholesterol with apolipoprotein B (LDL-C/ApoB) ratio (LAR), reflecting cholesterol content per atherogenic lipoprotein particle, may serve as a novel biomarker for sarcopenia risk. This study aimed to investigate the association between LAR and sarcopenia using data from the National Health and Nutrition Examination Survey (NHANES). Material and methods: Data from NHANES cycles 2011-2016 were analyzed between July 2024 and February 2025. Sarcopenia was defined using dual-energy X-ray absorptiometry (DXA)-derived appendicular lean mass (ALM) standardized to body mass index (BMI). Multivariable logistic regression, restricted cubic spline (RCS) regression analysis, subgroup analysis, and interaction tests were applied to evaluate the relationship between LAR and sarcopenia, adjusting for covariates. Results: A negative correlation between LAR and sarcopenia was observed in 3,235 participants included in the study (OR = 0.399, 95% CI: 0.224-0.712, Conclusions: Elevated LAR is significantly associated with lower sarcopenia risk, suggesting its potential role as a biomarker for muscle health. Further studies are needed to elucidate underlying mechanisms and validate these findings prospectively.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.